This content is from: Features
Indian patentability refined, post-Glivec
The Novartis decision on April 1 2013 turned the spotlight on section 3(d) of India’s Patent Act. A year on, Meenakshi Khurana looks at how this doctrine, along with obviousness standards, have been interpreted in recent cases
To access our in-house intelligence please request a trial here.
Read this article – and more – for a one-week period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here